Sym-021

点击蓝字 关注我们 过去很长一段时间，大家都默认全球顶尖的抗癌新技术、新突破集中在欧美国家，国内晚期患者只能被动等待、苦苦支撑。但2026年7月，国内肿瘤诊疗格局彻底迎来逆袭。 全球首例海外实体瘤CAR-T患者专程来华求医治疗，直观印证：中国原创肿瘤诊疗技术，已经实现从跟跑到领跑的跨越。 与此同时，国产个性化癌症疫苗、无创肠道菌群移植两大顶刊级疗法集中落地，所有疗效、结论均有顶刊临床数据实锤，精准对应晚期难治、多线耐药、术后高复发等核心患者人群，带来新曙光！ 里程碑！全球首例国际患者来华，接受国产实体瘤CAR-T治疗 2026年6月22日，中国自研技术成功打破欧美长达15年的技术垄断！全球首款获批用于实体瘤的CAR-T疗法——Satri-cel（舒瑞基奥仑赛/恺力美®）正式上市，专门针对晚期胃癌、胃食管结合部腺癌，彻底补齐了全球细胞免疫治疗在实体瘤领域的最大缺口。这款中国原创的抗癌黑科技，上市仅十余天，就斩获全球瞩目。 Satri-cel是国内完全自主研发、拥有全套自主知识产权的自体CAR-T细胞产品，核心靶向CLDN18.2实体瘤专属靶点。通俗来讲，该靶点具有极高的肿瘤特异性：正常人体仅胃黏膜有极少量表达，不会损伤健康组织；但70%胃癌、60%胰腺癌、30%食管癌患者的肿瘤细胞，会异常高表达该靶点，为精准治疗提供了绝佳条件。 简单来说，这款CAR-T就像精准定位的“肿瘤专属导弹”，只精准击杀癌细胞，不伤害正常器官，精准度、安全性远远优于传统放化疗，大幅降低了治疗副作用。 2026年7月6日，更是迎来了全球首位接受该疗法的海外国际患者——59岁的新西兰晚期胃十二指肠癌患者J先生。 J先生的治疗困境，是全球晚期实体瘤患者的普遍缩影。在新西兰当地，他已经完成所有标准化抗肿瘤治疗，但肿瘤持续进展恶化，当地医院已无有效治疗方案，彻底陷入无药可用的绝境。 为寻求生机，他多方对比全球前沿抗癌技术，最终锁定中国全新上市的CLDN18.2靶向CAR-T疗法——目前全球唯一获批用于晚期实体瘤的CAR-T技术。后续生物标志物检测显示，他CLDN18.2阳性、HER2阴性，完全匹配该疗法的治疗适应症。 值得骄傲的是，目前这款颠覆性的实体瘤CAR-T疗法，仅在中国落地上市、对外开放治疗。为了抓住最后的生存机会，Josh专程远赴上海求医。经过多学科专家的全面评估、方案定制，他顺利完成白细胞分离采集，专属的个体化CAR-T细胞已进入制备阶段，预计数周内即可回输开展治疗。 我们也相信，未来会有更多海外重症肿瘤患者选择来华，接受中国原创的前沿抗癌诊疗！ ▲图源“JICC”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除 国产CAR-T硬核实力实锤！超4年长期生存，刷新晚期胃癌生存期纪录，ORR 100% 对于病友和家属而言，新技术最核心的价值永远是真实疗效。这款全球独家实体瘤CAR-T能否真正稳住肿瘤、实现长期生存？我们不夸大宣传，直接参考ASCO年会、《柳叶刀》公开的超长随访硬核临床数据。 2026年ASCO年会重磅公布了该疗法超4.5年的长期随访数据。本次研究纳入的均是临床最高危的晚期胃癌患者：5例患者均一线化疗失败，80%合并凶险的腹膜转移，多数为预后极差的印戒细胞癌，属于传统治疗基本无解的难治人群。 最终临床结果相当亮眼：4例可评估患者的肿瘤客观缓解率（ORR）达到100%。其中2位患者经CAR-T治疗实现肿瘤大幅消退后，顺利接受手术根治，真正从晚期难治状态，迎来了临床根治的机会。 长期生存数据更是刷新晚期胃癌治疗纪录：全队列中位无进展生存期（PFS）达20.9个月，中位总生存期突破22.1个月。截至随访终点，仍有2例患者持续存活，随访时长分别达到58.1个月、51.1个月，充分证明这款CAR-T能够帮助高危晚期胃癌患者实现长期带瘤生存。 ▲图源“JCO，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除 此外，《柳叶刀》收录的典型案例，也解释了很多患者的疑惑：部分患者回输治疗第2周，肝脏病灶出现轻微增大，这并非病情进展，而是免疫细胞激活杀敌的正常“假性进展”。后续病灶持续缩小，治疗26周后，肿瘤体积已明显低于治疗基线，实现长期稳定控瘤。 ▲图源“Lancet”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除 近期三大顶刊级抗癌突破！疫苗+菌群疗法，攻克复发、耐药两大难题 除了领跑全球的实体瘤CAR-T，2026年7月上半月，国内肿瘤前沿领域集中爆发三项顶刊级重磅突破。所有技术均精准瞄准临床最棘手的两大难题：术后反复复发、免疫治疗彻底耐药，覆盖脑胶质瘤、胃肠癌、肺癌、黑色素瘤等多个高发难治癌种，适配广泛患者群体。 国产个性化DC疫苗登顶顶刊，脑胶质瘤1年生存率100% PART  01 胶质母细胞瘤是恶性程度最高的脑部肿瘤，被临床称为“癌中之王”。传统手术联合放化疗的标准方案下，患者中位生存期仅7-10个月，复发率极高，长期以来缺少有效的术后巩固手段，多数患者术后短期内即复发进展。 7月8日，北京天坛医院自研的新抗原DC疫苗ZSNeo-DC成功登顶《Nature Communications》，彻底打破脑胶质瘤的治疗僵局。和通用型疫苗不同，这款疫苗为患者个性化定制，依据个人肿瘤突变特征精准制备，针对性极强，杜绝泛化治疗的无效性。 大家可以通俗理解：这款疫苗相当于给人体免疫系统发放了专属“肿瘤识别手册”，精准训练免疫细胞识别、记忆癌细胞特征，在术后精准清除体内残留的微小病灶，从根源阻断肿瘤复发。 对应的Ib期临床（NCT04968366）数据格外亮眼：针对新诊断的胶质母细胞瘤患者，术后接种ZSNeo-DC疫苗巩固治疗，患者12个月总生存率（OS）达到100%，中位无进展生存期（PFS）提升至16.2个月，远超传统治疗的生存水平。 下图展示了一名术后复发性喉癌伴肺转移患者接受个性化新抗原脉冲树突状细胞疫苗治疗3个月前后的影像学检查，可见肺转移灶明显缩小。 ▲图源“Nat Commun”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除 北大肿瘤医院实锤：粪菌移植逆转胃肠癌PD-1耐药，疾病控制率40% PART  02 多数胃肠癌患者都会陷入同一个治疗死循环：PD-1免疫治疗初期有效，治疗一段时间后便会彻底耐药，后续无标准治疗方案可用。尤其是MSS型胃肠癌患者，天然对免疫治疗不敏感，是临床上公认的难治、高预后风险人群。 针对这一临床痛点，北大肿瘤医院开展的I期临床研究给出了全新破局思路，临床实锤：粪菌移植可有效逆转胃肠癌患者的PD-1免疫耐药，重启机体抗癌免疫力。 该研究（NCT04130763）共纳入10例多线治疗失败、PD-1耐药的晚期胃肠癌患者，包含8例胃癌、2例结直肠癌，全部为PD-L1低表达、MSS型难治患者，传统免疫、靶向治疗已基本失效，无有效救治方案。本次研究采用无创口服粪菌胶囊联合PD-1的治疗方案，全程无需肠镜、无需手术、无创伤，患者耐受度高。 最终临床数据显示：整体疾病控制率（DCR）达40%，客观缓解率（ORR）为20%（详见下图B），其中胃癌亚组疾病控制率（DCR）高达50%。 ▲图源“BMJ”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除 值得一提的是，其中两名患者实现长期免疫部分缓解： 患者LH008获得了最佳的iPR疗效，无进展生存期（PFS）为15个月。 患者LH010疗效稳定维持超19个月（详见下图C）。 ▲图源“BMJ”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除 总之，这组核心数据直接证实：肠道菌群紊乱是胃肠癌患者免疫耐药的核心诱因，重塑健康肠道微生态，能够有效唤醒休眠的抗癌免疫细胞，成功逆转耐药困境。 《自然医学》重磅实锤：菌群移植让肺癌一年生存率100%，黑色素瘤缓解率75% PART  03 2026年《Nature Medicine》发布的FMT-LUMINATE Ⅱ期多中心临床研究（NCT04951583），用硬核临床数据印证了这一机制，彻底刷新了晚期耐药肿瘤的治疗认知。 该研究专门针对无高效标准方案的晚期肺癌、黑色素瘤患者，采用无创口服粪菌胶囊联合免疫治疗的模式，适配人群广、接受度高。研究共筛选59名晚期患者，最终纳入40人，分为肺癌、黑色素瘤两大队列开展对照研究。 1、非小细胞肺癌队列数据格外惊艳：客观缓解率（ORR）高达80%（95% Cl：58.4-91.9），远超单纯PD-1治疗39%-46%的传统数据，疾病控制率（DCR）达95%。最重磅的是，所有入组患者一年生存（OS）率达到100%（详见下图B），一年无进展生存（PFS）率达65%（详见下图A），大幅刷新了晚期肺癌多线耐药后的生存纪录。 ▲图源“Nat Med”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除 2、黑色素瘤患者同样获益显著：客观缓解率（ORR）达75%（95% Cl：53.1-88.8），11名患者肿瘤大幅缩小，4名患者病灶完全消失、达到临床完全缓解（CR），疾病控制率（DCR）达75%，一年总生存率达79%（95%Cl：62.9-99.6，详见下图D），为多发转移、多线耐药的难治黑色素瘤患者，开辟了全新的治疗突破口。 ▲图源“Nat Med”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除 小编寄语 当下的肿瘤治疗，早已跳出单一放化疗、靶向治疗的传统模式，迈入“精准击杀病灶+修复机体免疫+长效防复发”的综合治疗新时代。 目前多项前沿抗癌新技术、创新药物临床试验正在持续招募患者，适配常规治疗效果不佳、出现免疫耐药、病情反复，以及想要提前干预、降低术后复发风险的肿瘤病友。 如果你对当前治疗方案不满意，正深陷耐药、复发的治疗困境，不愿轻易放弃治疗机会，可扫文末二维码，将病理报告、近期影像检查资料及全程治疗记录等，提交至国际干细胞与免疫细胞研究医学部，进行初步评估，精准匹配适配的前沿治疗方案与临床试验入组机会。 参考资料 [1]Zhang Y,et al.Fecal microbiota transplantation combined with anti-PD-1 therapy in refractory microsatellite-stable gastric cancer: a phase I feasibility and safety study. J Immunother Cancer. 2026 Mar 23;14(3):e013823. https://jitc.bmj.com/content/14/3/e013823 [2]Chang Liu,et al.Long-term follow-up of satric abtagene autoleucel (satri-cel) as sequential therapy after first-line treatment for advanced gastric cancer: A subgroup analysis.. J Clin Oncol , 2557-2557(2026). https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.2557 [3]Qi C,et al.Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial[J]. The Lancet, 2025. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00860-8/fulltext [4]Zhang Y,et al.Personalized neoantigen-pulsed autologous dendritic cells in newly-diagnosed glioblastoma: a phase Ib trial. Nat Commun. 2026 Jul 4.  https://www.nature.com/articles/s41467-026-75066-w 本文为“国际干细胞与免疫细胞研究”原创，转载需授权 干细胞与免疫细胞研究 入群免费领取抗癌 细胞资讯｜新技术｜新药研发｜权威专家 资料 求分享 求收藏 求点击 求在看

日报精选医学文献 今日精选20篇医学文献，查看更多请点击阅读原文 本文支持继续浏览摘要内容；完整摘要、收藏文章、订阅管理等完整功能，请前往小程序「医研日新」。前往小程序查看更多与订阅收藏 1. Pseudokinase-converting mutation in protein kinase C alpha drives chordoid glioma by pathway rewiring. [Brain Neoplasms] Proceedings of the National Academy of Sciences of the United States of America | 2026-07-13 | IF 9.4 AI脊索样胶质瘤中存在PKCα D463H突变，该突变使其丧失催化活性但获得脚手架功能，可作为疾病诊断的分子标志物及潜在治疗靶点。 摘要Chordoid glioma (ChG) is a rare, low-grade brain tumor characterized by a novel recurrent point mutation, D463H, in the kinase domain of protein kinase C alpha (PKCα). The mutation is invariably an Asp to His substitution, suggesting a unique function beyond catalytic inactivation associated with other cancer-associated PKCα mutations. Here, we show that this mutation converts PKCα into a pseudoki...查看完整摘要 2. Targeting mitochondrial protease in diffuse gliomas. [Glioma] Molecular cancer therapeutics | 2026-07-13 | IF 5.3 AITR107作为新型ClpP激动剂，在IDH突变型胶质瘤中展现出优于现有药物ONC201的抗肿瘤活性，具有显著的临床转化价值。 摘要Caseinolytic protease proteolytic subunit (ClpP) is part of the mitochondrial ClpXP protease responsible for degrading damaged proteins in the matrix, thus maintaining metabolic homeostasis. Small molecule activators of ClpP (ClpP agonists) have recently shown great promise against metabolically active cancers. TR107, a novel ClpP activator, demonstrates potent and selective cytotoxicity against g...查看完整摘要 3. Combating Inflammation and Promoting Anabolism in Osteoarthritic Cartilage Defect With an MMP13-Sensing Dual-Drug Scaffold. [Osteoarthritis] Advanced science (Weinheim, Baden-Wurttemberg, Germany) | 2026-07-13 | IF 14.3 AI该MMP13响应型双药物支架通过智能化按需释药机制，为早期OA提供了一种精准调控炎症与软骨修复的微创治疗新策略。 摘要Osteoarthritis (OA) is a widespread degenerative joint condition marked by progressive cartilage breakdown, and a chronic inflammatory microenvironment, where conventional therapies largely fail to halt disease progression. To address this unmet need, an intra-articularly implantable, disease-responsive scaffold was developed for combinatorial treatment to simultaneously combat inflammation and pr...查看完整摘要 4. Hairyvein agrimony-derived nanovesicles in microneedles eradicate intracellular bacteria and reverse senescence to heal diabetic foot osteomyelitis. [Osteomyelitis] Journal of controlled release : official journal of the Controlled Release Society | 2026-07-13 | IF 10.5 AI该微针贴片为难治性DFO提供了一种无创、低毒的协同治疗方案，有望突破传统治疗的“三重瓶颈”，改善患者预后。 摘要The refractory nature of diabetic foot osteomyelitis (DFO) wounds constitutes a primary cause of disability among diabetic patients. However, currently employed interventions fall short of clinical requirements because of undefined targeting mechanisms, suboptimal wound repair, and significant adverse effects, necessitating innovative therapeutic strategies that transcend traditional paradigms. By...查看完整摘要 5. Methotrexate for hand osteoarthritis. [Osteoarthritis] The Cochrane database of systematic reviews | 2026-07-13 | IF 8.8 AI该综述旨在明确甲氨蝶呤这一传统抗风湿药能否为手部骨关节炎提供新的治疗选择，为优化临床用药方案提供高质量证据支持。 摘要This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the benefits and harms of methotrexate for people with osteoarthritis of the hand. 6. Sensor-based measures of knee brace adherence have low agreement with self-report methods: a multi-measure study among knee osteoarthritis patients. [Osteoarthritis] Osteoarthritis and cartilage | 2026-07-13 | IF 7.2 AI在评估膝关节骨关节炎患者的支具依从性时，自我报告方法存在明显高估倾向，建议临床试验和实践中采用客观监测手段以获取更准确的治疗依从性数据。 摘要To explore agreement between self-report and objectively measured adherence to brace wearing by patients with knee osteoarthritis. A single-arm observational analysis nested within the PROP OA randomised controlled trial (ISRCTN28555470). Of 237 adults with symptomatic knee osteoarthritis randomised to brace treatment, 60 were included in this sub-study investigating three different methods of ass...查看完整摘要 7. Developmental divergence in voice-reward circuitry differentiates autistic from typically developing children and adolescents. [Deafness] Proceedings of the National Academy of Sciences of the United States of America | 2026-07-13 | IF 9.4 AI自闭症青少年对社会声音处理的神经发育轨迹异常，表现为对母亲声音的依赖持续增强而非正常地向同伴声音转移，提示早期干预应关注社会声音处理网络的重塑。 摘要Adolescence is a period of profound social change marked by a developmental shift in attention and motivation from parents toward nonfamilial peers. Autism is a neurodevelopmental condition characterized by lifelong challenges in social communication. However, the neurobiological signatures of adolescent social reorientation in autism are poorly understood. Human voice processing is a primary driv...查看完整摘要 8. Chronic Rhinosinusitis and Nasal Polyps in Eosinophilic Granulomatosis With Polyangiitis: A Scoping Review. [Sinusitis] 综述 | International forum of allergy & rhinology | 2026-07-13 | IF 7.2 AI对于表现为CRSwNP的患者，应警惕EGPA可能，即使鼻窦活检未提示血管炎，仍需长期随访以排除系统性血管炎。 摘要Chronic rhinosinusitis (CRS) is one of the most common manifestations of eosinophilic granulomatosis with polyangiitis (EGPA), often preceding the diagnosis of systemic vasculitis by several years. The sinonasal presentation of EGPA typically resembles CRS with nasal polyps (CRSwNP), making it clinically indistinguishable from those without EGPA. This overlap frequently contributes to significant ...查看完整摘要 9. Detergent-like Toxicity Mechanism of Amyloid Cylindrins Revealed by Cross-Link Spin Labeling Electron Spin Resonance. [Neurodegenerative Diseases] Journal of the American Chemical Society | 2026-07-13 | IF 14.4 AI该研究揭示淀粉样蛋白寡聚体可能通过类洗涤剂机制破坏神经元膜，为理解神经退行性疾病发病机制及开发靶向膜损伤通路的新型治疗策略提供了重要理论基础。 摘要Amyloid oligomers are considered to be the most toxic species in neurodegenerative diseases, such as Alzheimer's, and Parkinson's, among others. A major challenge in studying amyloid oligomers has been their heterogeneous character, coupled with a lack of methods that can probe targeted, localized structural information. In this paper, we show that in detergent micelles, the oligomeric state of am...查看完整摘要 10. Histone H3K18 Lactylation Promotes the Malignant Progression of Wilms Tumor via a PSRC1/AKT/HIF-1α Positive Feedback Loop. [Wilms Tumor] Advanced science (Weinheim, Baden-Wurttemberg, Germany) | 2026-07-13 | IF 14.3 AIH3K18la/PSRC1/AKT/HIF-1α正反馈环路可作为肾母细胞瘤精准分型和靶向干预的潜在生物标志物，为改善高危患儿预后提供新策略。 摘要Nephroblastoma, also known as Wilms tumor (WT), is the most common pediatric renal malignancy. Current treatment regimens exhibit limited efficacy in high-risk patients and are associated with long-term adverse effects. Through gene set enrichment analysis (GSEA) and validation using clinical specimens, we identified aberrant glycolytic activity in WT, which drives lactate accumulation. Lactate is...查看完整摘要 11. LRRC4 Orchestrates AP2A1-Containing Clathrin-Coated Vesicles to Disrupt Mitochondrial Cristae and Restrict Glioblastoma Progression. [Glioblastoma] Advanced science (Weinheim, Baden-Wurttemberg, Germany) | 2026-07-13 | IF 14.3 AILRRC4-AP2A1-Mic60轴的发现为GBM提供了新的线粒体脆弱性靶点，靶向高尔基体-线粒体互作可能成为胶质母细胞瘤的创新治疗策略。 摘要Mitochondrial dynamics and metabolic homeostasis are pivotal for the aggressive progression of glioblastoma (GBM); however, how membrane-bound organelles modulate mitochondrial remodeling remains unclear. In this study, we identified LRRC4 as a Golgi-anchored tumor suppressor that coordinates a novel vesicle-to-mitochondrial axis to inhibit tumor growth. Using single-sample gene set enrichment ana...查看完整摘要 12. Cyclic Mechanical Loading of Cardiomyocytes via Pressure-Driven Non-Planar Membrane Deformation in a Bioreactor System. [Heart Failure] Advanced science (Weinheim, Baden-Wurttemberg, Germany) | 2026-07-13 | IF 14.3 AI该研究建立的生物反应器平台可模拟不同压力条件下心肌细胞的力学响应，为理解心肌肥厚和心力衰竭的发病机制提供了体外研究工具。 摘要We introduce a novel bioreactor system that applies cyclic strain through controlled non-planar membrane deformation. The membrane deformation is driven by tunable pressure profiles spanning clinically reported end-diastolic pressure ranges observed in physiological and disease-associated conditions. Applied pressure was quantitatively related to spatial membrane strain through three-dimensional m...查看完整摘要 13. A Spatially Directed Microneedle Patch Enables Intratumoral Co-Delivery of FOLFIRINOX, Surufatinib, and Anti-PD-1 for Chemo-Immunotherapy of Pancreatic Ductal Adenocarcinoma. [Adenocarcinoma] Advanced science (Weinheim, Baden-Wurttemberg, Germany) | 2026-07-13 | IF 14.3 AI微针贴片局部共递送FOLFIRINOX、靶向药及免疫检查点抑制剂，可突破PDAC纤维化屏障，在降低全身毒性的同时重塑免疫微环境，为晚期胰腺癌提供新型联合治疗平台。 摘要Pancreatic ductal adenocarcinoma (PDAC), a lethal malignancy with a 5-year survival of 13%, faces limited therapeutic efficacy due to fibrotic barriers that block drug access to the therapeutic site, systemic toxicity of conventional chemotherapy, and an immunosuppressive tumor microenvironment (TME). Therapeutic agents with different functions, including FOLFIRINOX (FFX), surufatinib (SUR), and a...查看完整摘要 14. Microenvironment-Responsive Nanomedicine Enables Vertical Modulation of Mitochondrial Pathological Networks in Myocardial Ischemia-Reperfusion Injury. [Myocardial Infarction] Advanced science (Weinheim, Baden-Wurttemberg, Germany) | 2026-07-13 | IF 14.3 AIBIM纳米制剂通过三重机制协同干预MIRI病理网络，为急性心肌梗死再灌注治疗后心肌保护提供了一种具有临床转化潜力的精准治疗新策略。 摘要Myocardial ischemia-reperfusion injury (MIRI) is a severe and largely unavoidable complication of reperfusion therapy and remains a major determinant of poor outcomes after acute myocardial infarction. Here, we developed a mitochondria-targeted, ischemic microenvironment-responsive nanotherapeutic, termed Berberine/Isoliensinine-loaded Melanin Nanocomposite (BIM), by co-encapsulating the anti-infl...查看完整摘要 15. Versatile Detection of Cellular Protein via Fluorescence Anisotropy. [Neurodegenerative Diseases] Advanced science (Weinheim, Baden-Wurttemberg, Germany) | 2026-07-13 | IF 14.3 AICFAST技术为药物研发提供了一种快速、经济且高通量的蛋白检测工具，可加速靶点验证和先导化合物筛选。 摘要Protein detection is a cornerstone of life science research. Here, we present Cell Lysate Fluorescence Anisotropy (CFAST), a versatile and accessible alternative cellular protein detection method. CFAST measures cellular protein levels through changes in fluorescence anisotropy of a long lifetime triangulenium dye-labeled nanobody probe. The minimal steps of centrifugation and nuclease incubation ...查看完整摘要 16. Neural checkpoint therapy in lung cancer. [Adenocarcinoma] Trends in cancer | 2026-07-13 | IF 14.3 AINav1.8+神经元-CGRP轴可能成为肺癌免疫治疗的新靶点，通过神经检查点阻断有望将免疫冷肿瘤转化为热肿瘤，从而增强免疫检查点抑制剂疗效。 摘要Sensory nerves are emerging as regulators of tumor immunity. A newly identified Nav1.8+ neuron-calcitonin gene-related peptide axis in lung adenocarcinoma links nociceptive signaling to impaired tertiary lymphoid structure formation and immune escape, suggesting that neural checkpoint blockade may help remodel immune-cold tumors and improve immunotherapy responses (Ho et al.). 17. Preclinical and clinical efficacy of the HDAC6 inhibitor ricolinostat in combination with BCR pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia. [Leukemia] 信函 | Blood cancer journal | 2026-07-13 | IF 12.9 AIHDAC6抑制剂ricolinostat与BCR通路抑制剂联用对复发/难治性CLL显示出协同抗肿瘤活性，可能成为改善疗效的潜在治疗方案。 18. Deep learning-based CD8+ T cell model for predicting prognosis and‌ targeted immunotherapy benefit in ccRCC. [Carcinoma] NPJ digital medicine | 2026-07-13 | IF 12.4 AIDL-CD8T模型可从常规H&E染色病理图像无创预测ccRCC患者免疫治疗获益，为精准选择靶向联合免疫治疗方案提供新工具。 摘要Deep learning holds significant promise for improving clear cell renal cell carcinoma (ccRCC) diagnosis and treatment. However, studies concerning tumor microenvironment (TME) based on pathological images and artificial intelligence are very limited. In this multi-center cohort study, we developed a deep learning-based CD8+ T cell inflammation signature (DL-CD8T) for ccRCC from hematoxy...查看完整摘要 19. Impact of an AI algorithm for multi-day prediction of incident atrial fibrillation on clinical decision-making: PROVISION-AF study. [Atrial Fibrillation] NPJ digital medicine | 2026-07-13 | IF 12.4 AIAI风险评估工具能显著提升非专科医生的房颤识别能力，尤其在排除低风险患者方面表现优异，有望成为基层医疗和门诊场景中的实用辅助决策工具。 摘要Atrial fibrillation (AF) is frequently asymptomatic and often remains undetected until complications arise. Although artificial intelligence (AI)-enabled electrocardiography (ECG) can predict incident AF from sinus rhythm ECGs, its influence on physician risk assessment in simulated clinical settings remains uncertain. We developed a deep learning model to predict multi-day AF risk using non-AF 12...查看完整摘要 20. Portable RF brain scanner enables stroke type detection using deep learning. [Stroke] NPJ digital medicine | 2026-07-13 | IF 12.4 AI该便携式射频脑扫描系统可帮助急诊医生快速区分中风类型，为及时精准治疗决策提供辅助工具，有望改善患者预后。 摘要Stroke remains a leading cause of mortality worldwide, demanding rapid, accurate diagnosis; distinguishing stroke types matters because treatments differ significantly. Using a recently developed, non-invasive brain scanner integrating a 16-antenna radio-frequency array, we present a deep-learning model that distinguishes the two main stroke types. We employ masked autoencoder-based self-supervise...查看完整摘要 在小程序获取完整功能 收藏文章、管理订阅、查看本期完整摘要与个性化内容，请前往小程序「医研日新」。 前往小程序查看更多内容 免责声明：仅供学术交流参考，不构成任何医学建议或诊疗指导